For personal use only

ASX ANNOUNCEMENT

Actinogen pivotal Alzheimer's disease trial demonstrates trends toward clinical benefit in older patients and favourable longer term safety profile

Sydney, 19 November 2026. Actinogen Medical ASX: ACW ("ACW" or "the Company") today announces topline results from its pivotal, placebo-controlled XanaMIA trial of oral emestedastat (Xanamem®) over 36 weeks of treatment in 247 patients with mild to moderate Alzheimer's disease (AD) and elevated levels of the pTau181 blood biomarker.

Summary:

- In the overall population, Xanamem was numerically, but not statistically, superior to placebo for the primary endpoint of delayed disease progression, measured by the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB)
- Clinically significant and sustained benefit of 30% disease slowing was observed in older participants, supporting a new patent filing covering Xanamem treatment in older, more advanced AD patients, who are underserved by existing therapies and newer ones in development
- Xanamem was safe and well tolerated over the treatment period of 36 weeks
- In the Open Label Extension (OLE) phase of the trial, disease stabilization over 24 weeks (no mean progression) was observed in the first 29 participants with 24 weeks of active Xanamem therapy and therefore the OLE phase will continue in order to gather additional data
- The next OLE data milestone to be reported when approximately 100 participants have reached at least 24 weeks of treatment (Q1 CY2027)
- The Company is well-funded to CY2028, with $18.9m[1] cash on hand and no debt.

Detailed findings from the topline XanaMIA trial results are:

1. Xanamem was numerically, but not statistically, superior to placebo for the primary endpoint of delayed disease progression, measured by the CDR-SB at Weeks 12, 24 and 36, with a mean Xanamem benefit compared with placebo of 0.10 CDR-SB points at Week 36 (p = 0.65)
2. A statistically and clinically significant benefit on the CDR-SB zero progression rate (40% vs. 22%, p=0.02) for Xanamem was observed in the prespecified analysis of participants above the median age of 75 years, together with a clinically significant benefit of 30% disease slowing (mean CDR-SB superiority of 0.39 points at Week 36, p=0.22) – for context, this rate of disease slowing is similar to that claimed by Eli Lilly and Eisai for their approved anti-amyloid drugs
3. Small trends towards superiority of Xanamem vs. placebo on the key secondary endpoints of cognition and "Activities of Daily Living" were observed
4. The previously established, favourable safety profile for Xanamem 10 mg administered daily for up to 12 weeks was replicated over the longer treatment period of 36 weeks and no serious adverse events were attributed to Xanamem

® Xanamem is a registered trademark of Actinogen Medical Limited

[1] Unless stated otherwise, all financial data is in Australian dollars

5. Unblinding of data used by the Independent Data Monitoring Committee (DMC) in January 2026, for its interim analysis of trial-futility, showed a statistically significant Xanamem treatment benefit of 0.58 points (p=0.03, n=88) on the prespecified, interim analysis Week 24 CDR-SB endpoint, which was not fully sustained in the final analysis of 247 participants.

Available data from the XanaMIA OLE phase of the trial has also been reviewed and shows an encouraging lack of progression in the CDR-SB at 24 weeks in the first 29 participants to reach that timepoint. Continuation of the OLE phase will provide important long-term data on Xanamem treatment and aims to demonstrate durable treatment benefits. The next OLE data milestone will be reported in Q1CY2027 when approximately 100 participants have reached at least 24 weeks.

The Company intends to explore the XanaMIA results with potential co-development partners interested in novel AD therapies, with a focus on the encouraging data observed for older participants, who represent more than 70% of patients with Alzheimer's disease. Given its established safety profile in more than 500 participants and lack of drug-drug interaction potential, Xanamem is particularly well suited as a treatment for the older, more complex AD population, most of whom are on multiple medications including older AD treatments like donepezil.

Immediate steps have been taken to conserve cash by focusing expenditure on the OLE trial, suspending future phase 3 expenditure, expanding the intellectual property portfolio to include the new XanaMIA trial finding on older age, business development outreach, strategic portfolio planning, and finalizing XanaMIA analyses.

As of the date of this announcement, the Company had a cash balance of $18.9 million, and a significant accrued R&D tax incentive given the substantial amount of eligible R&D spend undertaken in the first half of FY2027. As the XanaMIA trial is closed out and with other cost saving initiatives being undertaken, the Company's cash commitments will drop substantially from early CY2027. The Company has no debt. This strong balance sheet provides a cash runway into CY2028 and enables the Company to complete evaluation of the XanaMIA data to determine the optimal strategy for the future development of Xanamem.

Actinogen's CEO, Dr Steven Gourlay, commented:

"Following our topline analysis of the XanaMIA trial we remain confident in the risk-benefit profile of Xanamem in mild to moderate Alzheimer's disease, with notable findings of clinically significant disease slowing in older participants, who represent a poorly served and large segment of the market. Our strong balance sheet provides optionality to fully explore the trial data with potential partners over the coming months and determine the optimal development path for Xanamem. We sincerely thank everyone for their ongoing support of Xanamem development including patients and their families living with Alzheimer's disease, as well our shareholders."

The Company will be holding a webinar at 11.00am (AEDT) this morning to discuss the trial results. **Register for the webinar** at any time through to the 11.00am start at: **https://tinyurl.com/mr3js44b**

A recording of the webinar will be available on the Company's InvestorHub site and YouTube channel as soon as possible following the event.

A copy of the webinar presentation is attached to this announcement.

View this announcement on our InvestorHub: https://investors.actinogen.com.au/link/Pmodbe

ENDS

For personal use only

Dr Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E. steven.gourlay@actinogen.com.au

Investors

Michael Roberts
Communications
M: +61 423 866 231
E. michael.roberts@actinogen.com.au

Media

George Hazim
Media & Public Affairs Australia
M: +61 417 516 262
E: georgehazim@mediaaffairs.com.au

For personal use only

Announcement authorised by the Board of Actinogen Medical Limited

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company in the late clinical stages of development for Xanamem® (emestedastat), its novel oral therapy for Alzheimer's disease. Xanamem also has other applications in diseases driven by elevated tissue cortisol including depression. The Company is based in Sydney, Australia with operations and clinical trials in Australia and the US. Xanamem has been studied in eight clinical trials with more than 500 people treated to date and has a promising safety and efficacy profile with treatment up to 36 weeks.

About the phase 2b/3 XanaMIA pivotal trial and Open Label Extension (OLE) phase

The XanaMIA trial was a randomized (1:1), double-blind, placebo-controlled phase 2b/3 trial evaluating Xanamem 10 mg versus placebo over 36 weeks in 247 participants across Australia and the United States. On 19 November 2026 Actinogen reported the initial results from the trial, showing trends towards overall slowing of disease progression and clinically significant slowing in older participants. Further analyses are on-going. The OLE phase of the trial is on-going following closure of enrolment of 168 participants in November 2026.

About Xanamem (emestedastat)

Xanamem's novel mechanism of action is to control the level of cortisol in brain, liver and adipose tissue (fat) through the inhibition of the tissue cortisol synthesis enzyme, 11β-HSD1, without blocking normal production of cortisol by the adrenal glands. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels of tissue cortisol control in regions where 11β-HSD1 is highly expressed such as the hippocampus and grey matter in the brain, as well as in liver and adipose tissue. Chronically elevated cortisol is associated with progression in Alzheimer's Disease and excess cortisol is known to be toxic to brain cells. Elevated cortisol is also associated with more severe forms of depression. Xanamem has demonstrated excellent target enzyme engagement and in human trials has shown potential benefit in older people with Alzheimer's disease and anti-depressive benefits in patients with moderately severe depression. To view Xanamem's two-minute Mechanism of Action animation, click here.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered "at-risk statements" - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realized.

ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.

For personal use only

Actinogen

XanaMIA Alzheimer's disease trial demonstrates clinically significant trend toward benefit in participants over 75 years but not in overall trial population

Xanamem demonstrates good long-term safety and tolerability with a promising rate of disease slowing in older Alzheimer's patients

Topline Results Webinar 19 November 2026

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

This presentation is not for general distribution or third party reliance or use.

This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.


Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.

To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation.


ersonal use only

Online Q&A


1. Click on the Q&A icon



2. Type your question in the new Q&A window




3. Hit enter on your keyboard to submit your message



ersonal use only

XanaMIA trial design and methods

A double-blind, randomized, 36-week, 2-arm clinical trial to assess safety, tolerability, and efficacy of Xanamem 10 mg daily in patients with mild to moderate AD (MMSE 18-26)



Primary Endpoint	Key Secondary Endpoints
CDR-SB change from baseline to 36 weeks	Change from Baseline to Week 36 in: • Global Cognitive Test Battery (CTB) • Amsterdam Instrumental Activities of Daily Living Questionnaire – short version (A-IADL-Q-SV)

ersonal use only

Key baseline characteristics for overall population


Generally well-balanced between groups

	Xanamem	Placebo
Age (mean, SD)	75.4 (7.5)	73.4 (8.6)
Sex, female (N, %)	63 (51.2)	57 (46.3)
Concomitant AD medications, yes (N, %)	74 (60.2)	75 (61)
ApoE4 carriers (N, %)	93 (75.6)	77 (62.6)
MMSE Total Score (mean, SD)	21.8 (3.4)	21.8 (3.1)
CDR-SB Score (mean, SD)	4.27 (1.84)	4.29 (2.09)
pTau-181 level (pg/ml) (mean, SD)	3.02 (2.13)	2.75 (1.22)
pTau-217 level (pg/ml) (mean, SD)	0.98 (1.32)	0.81 (0.48)

ersonal use only

Primary endpoint: small overall CDR-SB benefit


Effect size 0.10 points at end of treatment, not statistically significant (p = 0.65 Week 36)



ersonal use only

Major Xanamem trend in prespecified age > 75 years

CDR-SB effect size 0.39 points, p = 0.22 at Week 36




* 30% slowing similar to approved antibody therapies; older people have higher 11β-HSD1

Personal use only

Clear benefits in response rates in older participants

40% Xanamem stable (no progression) vs. 22% Placebo for age > 75 years*



For context, stable disease claim in donanemab trials is similar at 47% vs. 29% at one year

* Statistically significant: rate of stable or improved score of CDR-SB at end of treatment; donanemab data Sims et al. 2023

ersonal use only

Major unmet need in Alzheimer's care for adults older than 75

Alzheimer's patients older than 75 represent more than two thirds of the market


- 5.5 million Americans age 75+ live with Alzheimer's, accounting for 74% of U.S. cases among adults 65 and older. [1]
- ~80% of Alzheimer's cases among adults ages 75–84 were mild or moderate. [2]
- Recently approved Alzheimer's drugs are for earlier stage disease called "Mild Cognitive Impairment" as well as "Mild Alzheimer's disease" – e.g. early intravenous lecanemab uptake was about 80% lower at age 75+ than at ages 66–74. [3, 4]
- An estimated 32 million people had Alzheimer's disease worldwide in 2020. By 2050, the global population age 80+ is projected to triple to 426 million. [5, 6]

ersonal use only

[1] Alzheimer's Association, 2026 Facts and Figures, Fig. 4. [2] Yuan et al., J Alzheimers Dis, 2021. [3] U.S. prescribing information for Leqembi and Kisunla, §1. [4] Zhou et al., JAMA Network Open, 2025. [5] Gustavsson et al., Alzheimer's & Dementia, 2023, Table 3. [6] WHO, Ageing and health, 2025.

Slight benefit of Xanamem on cognition


Cognitive performance measured by computerized testing, p = 0.59



ersonal use only

Slight benefit on daily functioning overall

A-IADL-Q-SV “Amsterdam” activities of daily living questionnaire



ersonal use only


Other preliminary findings

- Available data from the XanaMIA OLE phase indicates disease stabilization in the mean CDR-SB in the first 29 participants who have reached 24 weeks on active Xanamem
- Trends towards reduction in neuroinflammation markers GFAP, neurofilament light
- No trends towards reduction in Alzheimer's disease biomarkers such as pTau
- Excellent safety profile consistent with prior trials
- No serious adverse events attributed to Xanamem

ersonal use only

The XanaMIA interim analysis was strongly positive

Effect sizes 0.58 at Week 24, p = 0.03; 0.38 at Week 36, p = 0.39



	Week 12	Week 24	Week 36
n (Xanamem)	70	43	29
n (Placebo)	72	45	23

ersonal use only


Conclusion

- The Company sincerely thanks everyone who has supported Xanamem development up to this point including patients and their families living with Alzheimer's disease, as well our shareholders
- The risk-benefit profile of Xanamem is highly suited to treatment in mild to moderate Alzheimer's disease, with notable findings of activity in older participants, who represent a poorly served and large segment of the market
- In patients over 75 a statistically significant disease stabilization rate was observed together with disease slowing of 30% (for comparison, Eli Lilly claim 22% for donanemab, Eisai 27% for lecanemab)
- The Open Label Extension (OLE) phase disease shows stabilization over 24 weeks (no mean progression) in the first 29 participants on Xanamem - OLE phase to continue
- Next OLE milestone when approximately 100 participants reach ≥24 weeks of treatment (Q1 CY2027)
- Balance sheet (cash balance $18.9 million and no debt) provides optionality to fully explore the trial data with potential partners over the coming months and determine the optimal development path for Xanamem


ersonal use only

Online Q&A


1. Click on the Q&A icon



2. Type your question in the new Q&A window



3. Hit enter on your keyboard to submit your message



ersonal use only

Contacts

Will Souter
CFO & Investor Relations
M: +61 402 035 716
E. will.souter@actinogen.com.au

Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E. steven.gourlay@actinogen.com.au

Join the Actinogen Investor Hub:
https://investors.actinogen.com.au/

ersonal use only